Skip Navigation


JAC Advance Access originally published online on April 8, 2008
Journal of Antimicrobial Chemotherapy 2008 62(1):109-115; doi:10.1093/jac/dkn149
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/1/109    most recent
dkn149v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tillotson, G. S.
Right arrow Articles by Critchley, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tillotson, G. S.
Right arrow Articles by Critchley, I. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005–07: laboratory-based surveillance study

Glenn S. Tillotson1,*, Deborah C. Draghi2, Daniel F. Sahm2, Karla M. Tomfohrde2, Tena del Fabro2 and Ian A. Critchley1

1 Replidyne Inc., 1450 Infinite Drive, Louisville, CO 80027, USA 2 Eurofins Medinet Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA

Received 24 January 2008; returned 25 January 2008; revised 11 March 2008; accepted 11 March 2008


* Correspondence address. Replidyne Inc., 472 Wheelers Farms Road, Milford, CT 06460, USA. Tel: +1-203-301-2166; Fax: +1-203-301-2199; E-mail: gtillotson{at}replidyne.com

Objectives: The aim of this study was to describe the rates of antimicrobial susceptibility of Staphylococcus aureus from skin and wound infections reported from nine regions of the USA during 2005–07 and to identify the regional variation in patterns of resistance.

Methods: The Surveillance Network (TSN) comprises 296 laboratories across the nine census regions of the USA. TSN laboratories reported the susceptibility data for six antimicrobials by isolate with source and other relevant data. Antimicrobial susceptibility data were analysed by individual drug resistance, multidrug resistance and geographical distribution of resistance phenotypes.

Results: There were over 380 000 isolates of S. aureus tested and reported for the period 2005–07. Methicillin resistance was observed in 57.8% in 2007, with little change from 2005. There was little difference in rates of methicillin resistance between community and hospital strains, although strains from intensive care units (ICUs) tended to be slightly more resistant overall. Resistance to other antimicrobials was also reported. A regional variation in resistance rates was noted with the highest rates in the Central states and lowest in the New England and Mid-Atlantic regions. There was high activity observed with trimethoprim/sulfamethoxazole and gentamicin. Linezolid resistance was rare. Oxacillin resistance was similar among paediatric and elderly cohorts, whereas ciprofloxacin and clindamycin resistance was significantly (P < 0.01) more common in elderly patients when compared with both paediatric and adult populations. Less than a third of all isolates showed no resistance mechanism, 30.3%. Three distinct resistance phenotypes accounted for 46% of all resistant strains. Overall, there were more highly drug-resistant isolates from the ICU with four, five or six drug-resistant phenotypes accounting for over a third of all strains.

Conclusions: S. aureus has become methicillin-resistant in both the community and hospital settings; however, little change has been seen in the past 3 years. Multiresistant strains now are seen in all settings, but due to regional variation, empirical therapy should be guided by local susceptibility patterns. Currently, among the agents studied, only trimethoprim/sulfamethoxazole, gentamicin and linezolid exhibit susceptibility rates of >95%.

Keywords: S. aureus , methicillin resistance , multidrug resistance , skin infections , community-acquired , inpatient , ICU


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
D. Krievins, R. Brandt, S. Hawser, P. Hadvary, and K. Islam
Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2834 - 2840.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
C. Oefner, M. Bandera, A. Haldimann, H. Laue, H. Schulz, S. Mukhija, S. Parisi, L. Weiss, S. Lociuro, and G. E. Dale
Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity
J. Antimicrob. Chemother., April 1, 2009; 63(4): 687 - 698.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.